-

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case for Monsanto.

More than 100 government, farm, business and non-profit groups – including the U.S. government --joined amici briefs in support of Monsanto’s position, urging the nation’s highest court to affirm Congress’ intent in including a “Uniformity” provision in FIFRA, and prevent a patchwork of state laws and labelling requirements which would threaten businesses, the economy, and farmers. Read more about the amici support for Monsanto here.

Monsanto also released the following statement regarding the oral argument in Durnell:

“Congress enacted FIFRA to establish a uniform, nationwide framework governing pesticide registration and labeling, and companies should not face liability under state law for complying with federally approved and science-based labeling requirements. Allowing such claims to proceed invites a patchwork of state standards that conflict with the uniformity objective Congress prescribed in law and creates regulatory uncertainties that impede the development of new agricultural innovations. The security and affordability of the nation’s food supply depend on farmers’ and manufacturers’ ability to rely on the science-based judgments of federal regulators. Clarification from the Court is essential to restore uniformity, certainty, and the rule of law.”

Contacts

Media Contact:
Brian Leake
(314) 370.3285

Monsanto


Release Versions

Contacts

Media Contact:
Brian Leake
(314) 370.3285

More News From Monsanto

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable witho...

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (...

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026) – found that 82% worry about their own and their families' wellbeing due...
Back to Newsroom